DRUGMAKER News & Analysis

We take a closer look at the potential impact of remdesivir's nearly certain approval on our valuation model for Gilead.

Though Morningstar views the healthcare sectors in both the US and Australia as fairly valued overall, there is a handful of buying opportunities...

Bristol-Myers Squibb Co says it will buy Celgene Corp for about $105bn, combining two of the world's largest cancer drug businesses in the biggest...